Braveheart Bio has disclosed its IPO path following licensing of Jiangsu Hengrui’s oral cardiac myosin inhibitor BHB-1893 for hypertrophic cardiomyopathy. The company reported encouraging Phase II data (NCT06516068) across both obstructive and nonobstructive HCM subtypes, and plans worldwide Phase III trials—oHCM starting in late 2026 and nHCM in early 2027—while Hengrui continues a Phase III program in China.